XNCR News and Press, Xencor Inc. From 05/07/20

Xencor (NASDAQ: XNCR ): Q1 GAAP EPS of -$0.14 beats by $0.25 . Revenue of $32.4M (-71.1% Y/Y) beats by $17.74M . Press Release More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news,

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter 2020 financial results after the market closes on Thursday, May 7, 2020. ...

The FDA has signed off on Fast Track status for Yantai, China-based RemeGen 's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE). More news on: GlaxoSmithKline plc, Mallinckrodt plc, Biogen Inc., Healthcare stocks news, Read more ...

Vir Biotechnology (NASDAQ: VIR ) has in-licensed non-exclusive rights to Xencor's (NASDAQ: XNCR ) Xtend Fc technology aimed at extending the half-lives of novel antibodies it is investigating for the potential treatment of COVID-19. More news on: Vir Biotechnology, Inc., Xencor, Inc., He...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-ex...

Xencor, Inc. (NASDAQ: XNCR) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “XNCR's 4Q19 EPS update was largely in line with our thesis as we see 2020 as a year of gaining visibility on the critical paths for wholly-owned T-cell ...

Image source: The Motley Fool. Xencor Inc   (NASDAQ: XNCR) Q4 2019 Earnings Call Feb 24, 2020 , 4:30 p.m. ET Operator Continue reading

Xencor, Inc. (XNCR) Q4 2019 Earnings Conference Call February 24, 2020 16:30 ET Corporate Participants Charles Liles - Associate Director and Head, Corporate Communications & Investor Relations Bassil Dahiyat - President and Chief Executive Officer John Kuch - Senior Vice Pre...

Xencor (NASDAQ: XNCR ): Q4 GAAP EPS of -$0.47 misses by $0.04 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...